Compare AEO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | SRRK |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.9B |
| IPO Year | 2004 | 2018 |
| Metric | AEO | SRRK |
|---|---|---|
| Price | $22.71 | $45.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $21.80 | ★ $51.20 |
| AVG Volume (30 Days) | ★ 4.1M | 852.2K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 95.35 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $5,328,652,000.00 | N/A |
| Revenue This Year | $4.06 | N/A |
| Revenue Next Year | $3.30 | $449.79 |
| P/E Ratio | $37.68 | ★ N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $9.27 | $22.71 |
| 52 Week High | $28.46 | $49.82 |
| Indicator | AEO | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 47.11 |
| Support Level | $9.89 | $42.74 |
| Resistance Level | $25.51 | $48.31 |
| Average True Range (ATR) | 1.18 | 2.02 |
| MACD | -0.20 | -0.42 |
| Stochastic Oscillator | 27.01 | 42.99 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.